Ezio MD - MacroGenics Senior Officer
| MGNX Stock | USD 2.77 0.21 7.05% |
Executive
Ezio MD is Senior Officer of MacroGenics
| Age | 71 |
| Address | 9704 Medical Center Drive, Rockville, MD, United States, 20850 |
| Phone | 301 251 5172 |
| Web | https://www.macrogenics.com |
MacroGenics Management Efficiency
The company has return on total asset (ROA) of (0.2215) % which means that it has lost $0.2215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6217) %, meaning that it created substantial loss on money invested by shareholders. MacroGenics' management efficiency ratios could be used to measure how well MacroGenics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.04 in 2025. Return On Capital Employed is likely to rise to -0.76 in 2025. At this time, MacroGenics' Net Tangible Assets are fairly stable compared to the past year. Debt To Assets is likely to rise to 0.11 in 2025, whereas Total Assets are likely to drop slightly above 287.5 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Renate Gloggner | Molecular Partners AG | 55 | |
| Emiko Bryant | PepGen | N/A | |
| PharmD Mordwinkin | Kezar Life Sciences | 43 | |
| Jolie JD | C4 Therapeutics | 48 | |
| Michelle MD | PepGen | 49 | |
| John JD | Edgewise Therapeutics | 61 | |
| Robert MD | Edgewise Therapeutics | N/A | |
| Wendy Chang | Zentalis Pharmaceuticals Llc | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Crystal Zuckerman | Pmv Pharmaceuticals | N/A | |
| FACP MD | Protagonist Therapeutics | 65 | |
| Richard Shames | Protagonist Therapeutics | 64 | |
| Mr MBA | C4 Therapeutics | 46 | |
| Kimberly Freeman | Zentalis Pharmaceuticals Llc | N/A | |
| Douglas CPA | Century Therapeutics | N/A | |
| Mary DeLena | PepGen | N/A | |
| Michael MD | Century Therapeutics | 53 | |
| Abha Bommireddi | Protagonist Therapeutics | N/A | |
| Gitanjali Jain | Kezar Life Sciences | N/A | |
| Scott MD | Protagonist Therapeutics | N/A | |
| Adrian MD | Zentalis Pharmaceuticals Llc | N/A | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.22 |
MacroGenics Leadership Team
Elected by the shareholders, the MacroGenics' board of directors comprises two types of representatives: MacroGenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MacroGenics. The board's role is to monitor MacroGenics' management team and ensure that shareholders' interests are well served. MacroGenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MacroGenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ezio Bonvini, Senior Vice President- Research | ||
| Jeffrey JD, General VP | ||
| Scott MD, CEO President | ||
| Beth Smith, Controller VP | ||
| Thomas Spitznagel, Senior Vice President - Bio Pharmaceutical Development and Manufacturing | ||
| Christopher MD, VP Communications | ||
| James Karrels, CFO, Sr. VP and Corporate Secretary | ||
| Lynn Cilinski, Principal Accounting Officer, VP, Controller and Treasurer | ||
| Jeffrey Peters, Vice President General Counsel | ||
| Ezio MD, Senior Officer | ||
| Eric Risser, Sr. VP of Bus. Devel. and Portfolio Management |
MacroGenics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MacroGenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.69) % | ||||
| Operating Margin | 0.49 % | ||||
| Current Valuation | 20.77 M | ||||
| Shares Outstanding | 62.76 M | ||||
| Shares Owned By Insiders | 2.65 % | ||||
| Shares Owned By Institutions | 93.56 % | ||||
| Number Of Shares Shorted | 5.28 M | ||||
| Price To Earning | (4.54) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.